Xeris Biopharma Holdings, Inc. (XERS)
NASDAQ: XERS · Real-Time Price · USD
5.41
-0.17 (-3.05%)
Mar 31, 2025, 12:09 PM EDT - Market open
Xeris Biopharma Holdings Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Xeris Biopharma Holdings stock have an average target of 5.92, with a low estimate of 4.00 and a high estimate of 8.00. The average target predicts an increase of 9.43% from the current stock price of 5.41.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Xeris Biopharma Holdings stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 1 | 1 | 2 | 2 | 3 |
| Buy | 2 | 1 | 1 | 1 | 1 | 2 |
| Hold | 0 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 3 | 3 | 4 | 4 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Leerink Partners | Leerink Partners | Buy Maintains $5 → $6 | Buy | Maintains | $5 → $6 | +10.91% | Mar 7, 2025 |
| Craig-Hallum | Craig-Hallum | Strong Buy Maintains $5 → $6.5 | Strong Buy | Maintains | $5 → $6.5 | +20.15% | Mar 7, 2025 |
| Piper Sandler | Piper Sandler | Hold Reiterates $3 → $4 | Hold | Reiterates | $3 → $4 | -26.06% | Mar 7, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $6.6 → $8 | Strong Buy | Reiterates | $6.6 → $8 | +47.87% | Mar 7, 2025 |
| Jefferies | Jefferies | Strong Buy Reiterates $4 → $6 | Strong Buy | Reiterates | $4 → $6 | +10.91% | Jan 29, 2025 |
Financial Forecast
Revenue This Year
267.55M
from 203.07M
Increased by 31.75%
Revenue Next Year
323.98M
from 267.55M
Increased by 21.09%
EPS This Year
-0.08
from -0.37
EPS Next Year
0.10
from -0.08
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 282.8M | 357.8M | 434.5M | ||
| Avg | 267.6M | 324.0M | 380.5M | ||
| Low | 250.4M | 293.4M | 336.3M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 39.2% | 33.7% | 34.1% | ||
| Avg | 31.8% | 21.1% | 17.5% | ||
| Low | 23.3% | 9.7% | 3.8% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 0.12 | 0.25 | 0.50 |
| Avg | -0.08 | 0.10 | 0.37 |
| Low | -0.18 | -0.15 | 0.21 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | 386.0% |
| Avg | - | - | 252.1% |
| Low | - | - | 98.5% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.